p.94 抽出テキスト

Circulation. 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 September 25, 2018 e365 CLINICAL STATEMENTS AND GUIDELINES

S6-38.	 Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs implantable defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071–8. S6-39.	 Kern KB. Optimal treatment of patients surviving out-of-hospital cardiac arrest. JACC Cardiovasc Intervent. 2012;5:597–605. S6-40.	 Perkins GD, Jacobs IG, Nadkarni VM, et al. Cardiac arrest and cardiopulmonary resuscitation outcome reports: update of the Utstein Resuscitation Registry Templates for out-of-hospital cardiac arrest: a statement for healthcare professionals from a task force of the International Liaison Committee on Resuscitation (American Heart Association, European Resuscitation Council, Australian and New Zealand Council on Resuscitation, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Southern Africa, Resuscitation Council of Asia); and the American Heart Association Emergency Cardiovascular Care Committee and the Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Circulation. 2015;132:1286–300. S6-41.	 Link MS, Myerburg RJ, Estes NA 3rd. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 12: emergency action plans, resuscitation, cardiopulmonary resuscitation, and automated external defibrillators: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e334–8. S6-42.	 Joglar JA, Page RL. Out-of-hospital cardiac arrest–are drugs ever the

answer? N Engl J Med. 2016;374:1781–2.

7 ONGOING MANAGEMENT OF VA

AND SCD RISK RELATED TO SPECIFIC DISEASE STATES

7.1 Ischemic Heart Disease

7.1.1 Secondary Prevention of SCD in Patients With Ischemic Heart Disease

S7.1.1-1.	 The AVID Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from nearfatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–83. S7.1.1-2.	 Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–302. S7.1.1-3.	 Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21: 2071–8. S7.1.1-4.	 Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748–54. S7.1.1-5.	 Raitt MH, Renfroe EG, Epstein AE, et al. ”Stable” ventricular tachycardia is not a benign rhythm: insights from the antiarrhythmics versus implantable defibrillators (AVID) registry. Circulation. 2001;103:244–52. S7.1.1-6.	 Owens DK, Sanders GD, Heidenreich PA, et al. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J. 2002;144:440–8. S7.1.1-7.	 Bass EB, Elson JJ, Fogoros RN, et al. Long-term prognosis of patients undergoing electrophysiologic studies for syncope of unknown origin. Am J Cardiol. 1988;62:1186–91. S7.1.1-8.	 Wyse DG, Friedman PL, Brodsky MA, et al. Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for death in follow-up. J Am Coll Cardiol. 2001;38:1718–24. S7.1.1-9.	 Maury P, Baratto F, Zeppenfeld K, et al. Radio-frequency ablation

as primary management of well-tolerated sustained monomorphic ventricular tachycardia in patients with structural heart disease and left ventricular ejection fraction over 30%. Eur Heart J. 2014;35:1479–85. S7.1.1-10.	 Pauriah M, Cismaru G, Magnin-Poull I, et al. A stepwise approach

to the management of postinfarct ventricular tachycardia using catheter ablation as the first-line treatment: a single-center experience. Circ Arrhythm Electrophysiol. 2013;6:351–6. S7.1.1-11.	 Larsen G, Hallstrom A, McAnulty J, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation. 2002;105:2049–57. S7.1.1-12.	 O’Brien BJ, Connolly SJ, Goeree R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2001;103:1416–21. S7.1.1-13.	 Buxton M, Caine N, Chase D, et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context. Health Technol Assess. 2006;10:iii–iv, ix–xi, 1–164 S7.1.1-14.	 Weiss JP, Saynina O, McDonald KM, et al. Effectiveness and costeffectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among medicare beneficiaries. Am J Med. 2002;112:519–27. S7.1.1-15.	 Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state-

ment on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329–45.

7.1.1.1 Coronary Artery Spasm

S7.1.1.1-1.	 Chevalier P, Dacosta A, Defaye P, et al. Arrhythmic cardiac arrest due to isolated coronary artery spasm: long-term outcome of seven resuscitated patients. J Am Coll Cardiol. 1998;31:57–61. S7.1.1.1-2.	 Myerburg RJ, Kessler KM, Mallon SM, et al. Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm. N Engl J Med. 1992;326: 1451–5. S7.1.1.1-3.	 Ahn JM, Lee KH, Yoo SY, et al. Prognosis of variant angina manifesting as aborted sudden cardiac death. J Am Coll Cardiol. 2016;68:137–45. S7.1.1.1-4.	 Matsue Y, Suzuki M, Nishizaki M, et al. Clinical implications of an implantable cardioverter-defibrillator in patients with vasospastic angina and lethal ventricular arrhythmia. J Am Coll Cardiol. 2012;60:908–13. S7.1.1.1-5.	 Takagi Y, Yasuda S, Tsunoda R, et al. Clinical characteristics and long-term prognosis of vasospastic angina patients who survived out-of-hospital cardiac arrest: multicenter registry study of the Japanese Coronary Spasm Association. Circ Arrhythm Electrophysiol. 2011;4:295–302. S7.1.1.1-6.	 Meisel SR, Mazur A, Chetboun I, et al. Usefulness of implantable cardioverter-defibrillators in refractory variant angina pectoris complicated by ventricular fibrillation in patients with angiographically normal coronary arteries. Am J Cardiol. 2002;89:1114–6. S7.1.1.1-7.	 JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008). Circ J. 2010;74:1745–62. S7.1.1.1-8.	 Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e344–426. S7.1.1.1-9.	 Morikawa Y, Mizuno Y, Yasue H. Letter by Morikawa et al regarding article, “coronary artery spasm: a 2009 update.” Circulation. 2010;121:e16. S7.1.1.1-10.	 Sasaki S, Tomita H, Shibutani S, et al. Usefulness of the wearable

cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circ J. 2014;78:2987–9.

7.1.1.2 Post CABG VT/VF

S7.1.1.2-1.	 Ascione R, Reeves BC, Santo K, et al. Predictors of new malig-

nant ventricular arrhythmias after coronary surgery: a case-control study. J Am Coll Cardiol. 2004;43:1630–8.

Downloaded from http://ahajournals.org by on October 7, 2026